Taming the beast: engineering strategies and biomedical potential of antibody-based cytokine mimetics

References

• Dinarello CA. Historical insights into cytokines. Eur J Immunol. 2007;37(S1):S34–S45. doi: 10.1002/eji.200737772
   PubMed Web of Science ®Google Scholar
• Miyajima A, Kitamura T, Harada N, et al. Cytokine receptors and signal transduction. Annu Rev Immunol. 1992;10(1):295–331. doi: 10.1146/annurev.iy.10.040192.001455
   PubMedGoogle Scholar
• Turner MD, Nedjai B, Hurst T, et al. Cytokines and chemokines: at the crossroads of cell signalling and inflammatory disease. Biochim Biophys Acta, Mol Cell Res. 2014;1843(11):2563–2582. doi: 10.1016/j.bbamcr.2014.05.014
   PubMed Web of Science ®Google Scholar
• Pires IS, Hammond PT, Irvine DJ. Engineering strategies for immunomodulatory cytokine therapies: challenges and clinical progress. Adv Ther. 2021;4(8):2100035. doi: 10.1002/adtp.202100035
   Google Scholar
• Saxton RA, Glassman CR, Garcia KC. Emerging principles of cytokine pharmacology and therapeutics. Nat Rev Drug Discov. 2023;22(1):21–37. doi: 10.1038/s41573-022-00557-6
   PubMed Web of Science ®Google Scholar
• Baldo BA. Side effects of cytokines approved for therapy. Drug Saf. 2014;37(11):921–943. doi: 10.1007/s40264-014-0226-z
   PubMed Web of Science ®Google Scholar
• Deckers J, Anbergen T, Hokke AM, et al. Engineering cytokine therapeutics. Nat Rev Bioeng. 2023;1(4):286–303. doi: 10.1038/s44222-023-00030-y
   PubMedGoogle Scholar
• Santollani L, Wittrup KD. Spatiotemporally programming cytokine immunotherapies through protein engineering. Immunol Rev. 2023;320(1):10–28. doi: 10.1111/imr.13234
   PubMed Web of Science ®Google Scholar
• Pini A, Viti F, Santucci A, et al. Design and use of a phage display library: human antibodies with subnanomolar affinity against a marker of angiogenesis eluted from a two-dimensional gel. J Biol Chem. 1998;273(34):21769–21776. doi: 10.1074/jbc.273.34.21769
   PubMed Web of Science ®Google Scholar
• Danielli R, Patuzzo R, Di Giacomo AM, et al. Intralesional administration of L19-IL2/L19-TNF in stage III or stage IVM1a melanoma patients: results of a phase II study. Cancer Immunol Immunother. 2015;64(8):999–1009. doi: 10.1007/s00262-015-1704-6
   PubMed Web of Science ®Google Scholar
• Look T, Puca E, Bühler M, et al. Targeted delivery of tumor necrosis factor in combination with CCNU induces a T cell–dependent regression of glioblastoma. Sci Transl Med. 2023;15(697):eadf2281. doi: 10.1126/scitranslmed.adf2281
   PubMed Web of Science ®Google Scholar
• Weiss T, Puca E, Silginer M, et al. Immunocytokines are a promising immunotherapeutic approach against glioblastoma. Sci Transl Med. 2020;12(564):eabb2311. doi: 10.1126/scitranslmed.abb2311
   PubMed Web of Science ®Google Scholar
• Codarri Deak L, Nicolini V, Hashimoto M, et al. PD-1-cis IL-2R agonism yields better effectors from stem-like CD8+ T cells. Nature. 2022;610(7930):161–172. doi: 10.1038/s41586-022-05192-0
   PubMed Web of Science ®Google Scholar
• Wu W, Chia T, Lu J, et al. IL-2Rα-biased agonist enhances antitumor immunity by invigorating tumor-infiltrating CD25+CD8+ T cells. Nat Cancer. 2023;4(9):1309–1325. doi: 10.1038/s43018-023-00612-0
   PubMedGoogle Scholar
• Holder PG, Lim SA, Huang CS, et al. Engineering interferons and interleukins for cancer immunotherapy. Adv Drug Delivery Rev. 2022;182:114112. doi: 10.1016/j.addr.2022.114112
   PubMed Web of Science ®Google Scholar
• Xue D, Hsu E, Fu Y-X, et al. Next-generation cytokines for cancer immunotherapy. Antib Ther. 2021;4(2):123–133. doi: 10.1093/abt/tbab014
   PubMedGoogle Scholar
• Moraga I, Wernig G, Wilmes S, et al. Tuning cytokine receptor signaling by re-orienting dimer geometry with surrogate ligands. Cell. 2015;160(6):1196–1208. doi: 10.1016/j.cell.2015.02.011
   PubMed Web of Science ®Google Scholar
• Mohan K, Ueda G, Kim AR, et al. Topological control of cytokine receptor signaling induces differential effects in hematopoiesis. Science. 2019;364(6442):eaav7532. doi: 10.1126/science.aav7532
   PubMed Web of Science ®Google Scholar
• Harris KE, Lorentsen KJ, Malik-Chaudhry HK, et al. A bispecific antibody agonist of the IL-2 heterodimeric receptor preferentially promotes in vivo expansion of CD8 and NK cells. Sci Rep. 2021;11(1). doi: 10.1038/s41598-021-90096-8
   Web of Science ®Google Scholar
• Yen M, Ren J, Liu Q, et al. Facile discovery of surrogate cytokine agonists. Cell. 2022;185(8):1414–1430.e19. doi: 10.1016/j.cell.2022.02.025
   PubMed Web of Science ®Google Scholar
• Lipinski B, Unmuth L, Arras P, et al. Generation and engineering of potent single domain antibody-based bispecific IL-18 mimetics resistant to IL-18BP decoy receptor inhibition. MAbs. 2023;15(1):2236265. doi: 10.1080/19420862.2023.2236265
   PubMed Web of Science ®Google Scholar
• Holliger P, Prospero T, Winter G. “Diabodies”: small bivalent and bispecific antibody fragments. Proc Natl Acad Sci, USA. 1993;90(14):6444–6448. doi: 10.1073/pnas.90.14.6444
   PubMed Web of Science ®Google Scholar
• Brinkmann U, Kontermann RE. The making of bispecific antibodies. MAbs. 2017;9(2):182–212. doi: 10.1080/19420862.2016.1268307
   PubMed Web of Science ®Google Scholar
• Plückthun A. Designed ankyrin repeat proteins (DARPins): binding proteins for research, diagnostics, and therapy. Annu Rev Pharmacol Toxicol. 2015;55(1):489–511. doi: 10.1146/annurev-pharmtox-010611-134654
   PubMed Web of Science ®Google Scholar
• Könning D, Zielonka S, Grzeschik J, et al. Camelid and shark single domain antibodies: structural features and therapeutic potential. Curr Opin Struct Biol. 2017;45:10–16. doi: 10.1016/j.sbi.2016.10.019
   PubMed Web of Science ®Google Scholar
• Valldorf B, Hinz SC, Russo G, et al. Antibody display technologies: selecting the cream of the crop. Biol Chem. 2022;403(5–6):455–477. doi: 10.1515/hsz-2020-0377
   PubMed Web of Science ®Google Scholar
• Roth L, Krah S, Klemm J, et al. Isolation of antigen-specific vhh single-domain antibodies by combining animal immunization with yeast surface display. In: Zielonka S Krah Seditors. Genotype phenotype coupling. New York (NY): Springer US; 2020. p. 173–189.
   Google Scholar
• Sellmann C, Pekar L, Bauer C, et al. A one-step process for the construction of phage display scFv and VHH libraries. Mol Biotechnol. 2020;62(4):228–239. doi: 10.1007/s12033-020-00236-0
   PubMed Web of Science ®Google Scholar
• Arras P, Yoo HB, Pekar L, et al. A library approach for the de novo high-throughput isolation of humanized VHH domains with favorable developability properties following camelid immunization. mAbs. MAbs. 2023;15(1). doi: 10.1080/19420862.2023.2261149
   Web of Science ®Google Scholar
• Arras P, Yoo HB, Pekar L, et al. AI/ML combined with next-generation sequencing of VHH immune repertoires enables the rapid identification of de novo humanized and sequence-optimized single domain antibodies: a prospective case study. Front Mol Biosci. 2023;10:1249247. doi: 10.3389/fmolb.2023.1249247
   PubMed Web of Science ®Google Scholar
• Vincke C, Loris R, Saerens D, et al. General strategy to humanize a camelid single-domain antibody and identification of a universal humanized nanobody scaffold. J Biol Chem. 2009;284(5):3273–3284. doi: 10.1074/jbc.M806889200
   PubMed Web of Science ®Google Scholar
• Sulea T. Humanization of camelid single-domain antibodies. In: Hussack G Henry K, editors. Single-domain antibodies. New York (NY): Springer US; 2022. p. 299–312.
   Google Scholar
• Spolski R, Li P, Leonard WJ. Biology and regulation of IL-2: from molecular mechanisms to human therapy. Nat Rev Immunol. 2018;18(10):648–659. doi: 10.1038/s41577-018-0046-y
   PubMed Web of Science ®Google Scholar
• Lin J-X, Leonard WJ. The common cytokine receptor γ chain family of cytokines. Cold Spring Harb Perspect Biol. 2018;10(9):a028449. doi: 10.1101/cshperspect.a028449
   PubMed Web of Science ®Google Scholar
• Dusheiko G. Side effects of? interferon in chronic hepatitis C. Hepatology. 1997;26(S3):112S–121S. doi: 10.1002/hep.510260720
   PubMed Web of Science ®Google Scholar
• Sleijfer S, Bannink M, Gool AR, et al. Side effects of interferon-α therapy. Pharm World Sci. 2005;27(6):423–431. doi: 10.1007/s11096-005-1319-7
   PubMedGoogle Scholar
• Zhou T, Damsky W, Weizman O-E, et al. IL-18BP is a secreted immune checkpoint and barrier to IL-18 immunotherapy. Nature. 2020;583(7817):609–614. doi: 10.1038/s41586-020-2422-6
   PubMed Web of Science ®Google Scholar
• Harwerth IM, Wels W, Marte BM, et al. Monoclonal antibodies against the extracellular domain of the erbB-2 receptor function as partial ligand agonists. J Biol Chem. 1992;267(21):15160–15167. doi: 10.1016/S0021-9258(18)42160-6
   PubMed Web of Science ®Google Scholar
• Müller-Newen G, Küster A, Wijdenes J, et al. Studies on the Interleukin-6-type cytokine signal transducer gp130 reveal a novel mechanism of receptor activation by monoclonal antibodies. J Biol Chem. 2000;275(7):4579–4586. doi: 10.1074/jbc.275.7.4579
   PubMed Web of Science ®Google Scholar
• George PM, Badiger R, Alazawi W, et al. Pharmacology and therapeutic potential of interferons. Pharmacol Ther. 2012;135(1):44–53. doi: 10.1016/j.pharmthera.2012.03.006
   PubMed Web of Science ®Google Scholar
• Knight V, Merkel P, O’Sullivan M. Anticytokine autoantibodies: association with infection and immune dysregulation. Antibodies. 2016;5(1):3. doi: 10.3390/antib5010003
   Google Scholar
• Cheng A, Holland SM. Anticytokine autoantibodies: Autoimmunity trespassing on antimicrobial immunity. J Allergy Clin Immunol. 2022;149(1):24–28. doi: 10.1016/j.jaci.2021.11.016
   PubMed Web of Science ®Google Scholar
• Duggan S. Caplacizumab: First Global Approval. Drugs. 2018;78(15):1639–1642. doi: 10.1007/s40265-018-0989-0
   PubMed Web of Science ®Google Scholar
• Keam SJ. Ozoralizumab: first approval. Drugs. 2023;83(1):87–92. doi: 10.1007/s40265-022-01821-0
   PubMed Web of Science ®Google Scholar
• Markham A. Envafolimab: First Approval. Drugs. 2022;82(2):235–240. doi: 10.1007/s40265-022-01671-w
   PubMed Web of Science ®Google Scholar
• Lin J, Lee SL, Russell AM, et al. A structure-based engineering approach to abrogate pre-existing antibody binding to biotherapeutics. PLoS One. 2021;16(7):e0254944. doi: 10.1371/journal.pone.0254944
   PubMed Web of Science ®Google Scholar